SANTA BARBARA, Calif., June 30, 2020
Bexson Biomedical, Inc. announced the addition of Bill Carson, MD as advisor to the company. Dr. Carson brings a valuable perspective to Bexson's R&D program and guidance for its novel ketamine delivery platform.
"We are excited to have Drs. Carson's experience and strategic vision on the Bexson team. Dr. Carson's many FDA approvals and commercial success while leading Otsuka illustrate his ability to optimize technology in our highly regulated industry," said Gregg Peterson, Bexson CEO.
Dr. Carson is the current Chairman of the Board, and former President & CEO of Otsuka Pharmaceutical Development & Commercialization. He is an internationally recognized pharmaceutical and biotechnology leader, who guided global approval of several drugs and digital medicines. According to Dr. Carson, "I am encouraged by Bexson's R&D programs and hopeful that the company's technologic innovations will provide better treatment options for opioid-dependent patients."
Bexson Biomedical, Inc. is a research stage company developing a proprietary ketamine-based subcutaneous treatment platform for pain management and mental health disorders. Visit at: www.bexsonbiomedical.com.
